Gene therapy for pulmonary hypertension: prospects and challenges
- PMID: 21219232
- DOI: 10.1517/14712598.2011.542139
Gene therapy for pulmonary hypertension: prospects and challenges
Abstract
Introduction: Recent evidence shows that pulmonary arterial hypertension (PAH) remains a fatal disease despite the introduction of new pharmacological treatments. New options are therefore needed and gene therapy approaches are a rational consideration based on emerging understanding of the genetic basis of PAH.
Areas covered: This review briefly discusses the recent developments in clinical management of PAH and the investigation of gene delivery techniques for pulmonary vascular disease from 1997 to 2010, relating this to improved understanding of disease pathogenesis during this period. There is a focus on bone morphogenetic protein receptor type 2, as mutations in this gene are clearly linked to disease pathogenesis and outcomes. The reader will gain insight into the gene vector strategies being used, the target cells and the specific genes being delivered as candidate therapeutic approaches for PAH.
Expert opinion: Various genes and strategies for delivery have achieved improvements in PAH in animal models, which is encouraging for the development of this technology for human application. The main limiting factor for clinical progress relates to gene delivery vector technology.
Similar articles
-
Viruses in pharmaceutical research: pulmonary vascular disease.Mol Pharm. 2011 Feb 7;8(1):56-64. doi: 10.1021/mp1003477. Epub 2010 Dec 22. Mol Pharm. 2011. PMID: 21138278 Review.
-
MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension.Expert Opin Ther Targets. 2013 May;17(5):557-64. doi: 10.1517/14728222.2013.765863. Epub 2013 Feb 2. Expert Opin Ther Targets. 2013. PMID: 23379818 Review.
-
Genetic basis of pulmonary arterial hypertension: current understanding and future directions.J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):33S-39S. doi: 10.1016/j.jacc.2004.02.028. J Am Coll Cardiol. 2004. PMID: 15194176 Review.
-
Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.Expert Opin Ther Targets. 2017 Feb;21(2):181-190. doi: 10.1080/14728222.2017.1275567. Epub 2016 Dec 28. Expert Opin Ther Targets. 2017. PMID: 28001443 Review.
-
[Female gender and pulmonary arterial hypertension: a complex relationship].G Ital Cardiol (Rome). 2012 Jun;13(6):448-60. doi: 10.1714/1073.11764. G Ital Cardiol (Rome). 2012. PMID: 22622125 Italian.
Cited by
-
Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.Mol Ther. 2012 Aug;20(8):1516-28. doi: 10.1038/mt.2012.70. Epub 2012 Apr 24. Mol Ther. 2012. PMID: 22525513 Free PMC article.
-
Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.J Am Coll Cardiol. 2016 May 3;67(17):2032-46. doi: 10.1016/j.jacc.2016.02.049. J Am Coll Cardiol. 2016. PMID: 27126531 Free PMC article.
-
Endothelial nanomedicine for the treatment of pulmonary disease.Expert Opin Drug Deliv. 2015 Feb;12(2):239-61. doi: 10.1517/17425247.2015.961418. Epub 2014 Nov 14. Expert Opin Drug Deliv. 2015. PMID: 25394760 Free PMC article. Review.
-
Current and emerging therapeutic approaches to pulmonary hypertension.Rev Cardiovasc Med. 2020 Jun 30;21(2):163-179. doi: 10.31083/j.rcm.2020.02.597. Rev Cardiovasc Med. 2020. PMID: 32706206 Free PMC article. Review.
-
Pulmonary arterial hypertension: advances in pathophysiology and management.Indian J Pharmacol. 2012 Jan;44(1):4-11. doi: 10.4103/0253-7613.91858. Indian J Pharmacol. 2012. PMID: 22345861 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical